IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026

POTOMAC, MD / / September 28, 2026 / IGC Pharma, Inc. AMEX:IGC ("IGC" or the "Company") today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset, IGC-AD1, for agitation in Alzheimer's dementia.CALMA achieved target enrollment with 168 participants…